Drugs / NJH395
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03696771 | Dec 2018 → Oct 2020 | carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NJH395 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03696771 ↗ |
| Action | Activate | “TLR7 agonism contributing to antitumor activity” PMID 36129967 ↗ Dec 2022 |
| Modality | Monoclonal antibody | “consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent” NCT03696771 ↗ |
| Route | Intravenous | “Administered Intravenously” NCT03696771 ↗ |
| Target | TLR7 | “a Toll-like receptor 7 (TLR7) agonist” PMID 36129967 ↗ Dec 2022 |